AN2 Therapeutics, Inc.
NASDAQ:ANTXBiotechnology
+$0.04 today
- Market cap
- $187.82M
- Beta
- -0.98
- P/E (TTM)
- -4.9
- EPS (TTM)
- -$1.01
Volume 0.97M
Average 0.29M
ANTX EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
AN2 Therapeutics, Inc.NASDAQ: ANTX
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -$10.03M, compared with -$10.65M a year earlier. Trailing-twelve-month EBITDA was -$35.85M.
Context
- EBITDA increased in 1 of the last 3 fiscal years.
What to watch
Whether EBITDA reaches the consensus estimate from 1 analysts of $0 (+100.0%) for the fiscal year ending Dec 2026, a step up from the -1188.0% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$10.03M-0.2% QoQ
- Last fiscal yearDec 2025
- -$35.17M-1188.0% YoY
- LTMMar 2026
- -$35.85M-213.1% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +5.8% | +100.0% | +94.2 pp |
| 1 year | -1188.0% | +100.0% | +1288.0 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (35.17M) USD
- Year-over-year change
- -1188.0%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (35.17M) | -1188.0% |
| FY2024 | 2024-12-31 | 3.23M | -34.1% |
| FY2023 | 2023-12-31 | 4.9M | +112.0% |
| FY2022 | 2022-12-31 | (40.88M) | -89.8% |
| FY2021 | 2021-12-31 | (21.54M) | — |
EBITDA vs competitors
How ANTX compares with its peers on the latest reported figures
- ANTX's LTM Mar 2026 EBITDA of -$35.85M is the 5th highest of the 6 companies compared; the peer median is -$11.36M.
- Its year-over-year change of -213.1% is the lowest of 6, against a peer median of +71.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $22.15M | +154.8% | — | 41.2% | |
| LTM Jun 2026 | -$9.46M | +71.7% | — | — | |
| LTM Mar 2026 | -$11.36M | +79.6% | — | 30.6% | |
| LTM Jun 2026 | -$32.35M | -89.8% | — | 32345.0% | |
| LTM Mar 2026 | -$35.85M | -213.1% | — | — | |
| LTM Mar 2026 | -$54.78M | +15.1% | — | — | |
| Peer median (excluding ANTX) | -$11.36M | +71.7% | — | 41.2% | |
Competitors are the stored peer set for ANTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 77K | 0 | 0 | 0 |
| Gross Profit | 0 | (77K) | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 16.91M | 29.51M | 54.87M | 40.49M | 24.77M |
| Selling, General & Admin | 4.67M | 12.75M | 14.76M | 14.07M | 13.34M |
| Operating Expenses | 21.57M | 42.19M | 69.64M | 54.55M | 38.11M |
| Depreciation & Amortization | 0 | 77K | 69.64M | 54.55M | 0 |
| EBITDA | (21.54M) | (40.88M) | 4.9M | 3.23M | (35.17M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (21.57M) | (42.26M) | (69.64M) | (54.55M) | (38.11M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 69K | 1.35M | 4.86M | 5.47M | 2.93M |
| Interest Expense | 0 | 514K | 0 | 0 | 0 |
| Other Income / Expenses | 31K | 1.31M | 4.9M | 3.23M | 2.94M |
| Income Before Tax | (21.54M) | (40.96M) | (64.73M) | (51.32M) | (35.17M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (21.54M) | (40.96M) | (64.73M) | (51.32M) | (35.17M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.50) | (2.79) | (2.74) | (1.72) | (1.16) |
| EPS (Diluted) | (1.50) | (2.79) | (2.74) | (1.72) | (1.16) |
| Weighted Avg Shares | 18.74M | 15.34M | 23.6M | 29.83M | 30.22M |
| Weighted Avg Shares (Diluted) | 18.74M | 15.34M | 23.6M | 29.83M | 30.22M |
AN2 Therapeutics, Inc.
NASDAQ:ANTX
Intrinsic Alpha fair value
Locked
Current Price
$4.95
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.